February 6th 2026
Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.
Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.
In a pair of lively debates at the International Stroke Conference 2026, experts from around the world discussed controversies in stroke care.
February 5th 2026
Clearer definitions, tailored programs and policies, and telestroke care could help close rural stroke care disparities.
February 4th 2026
Real-world inotuzumab ozogamicin boosts remission in relapsed/refractory B-cell ALL, supports transplant, and flags sinusoidal obstruction syndrome risk.
Access, Affordability for Low- and Moderate-Income Adults Under the ACA
A survey compares healthcare access and affordability among different types of coverage for low-and moderate-income adults.
Read More
UnitedHealth's Exit From ACA Exchanges Will Have a Modest Effect
The departure of UnitedHealth from most Affordable Care Act exchanges will have a relatively small effect on premiums across the country, but the effect could be more pronounced in rural areas and southern states.
Fewer Drugs on Specialty Tiers
Insurance plans offered through the Affordable Care Act are placing fewer drugs on the specialty tier of formularies than they were 2 years prior, according to a new study from Avalere.
Expensive Oral Agents Responsible for Cost Shifting in Cancer
Oral anticancer agents are being launched at significantly higher prices compared with a decade ago, which can prove a barrier to patient access, according to a new analysis published in JAMA Oncology.
Experts Share Final Thoughts on Delivering Better Value-Based Care in Oncology
Watch
Need for Stakeholder Participation in Developing Payment Models
Is a Single-Payer System the Answer to Our Healthcare Woes?
Impact of Consolidation on the Value of Care Delivery
Limitations of ICER's Value Assessment Framework Tool
Evidence Blocks: Patient Versus Societal Costs
The ASCO Value Framework as a Tool for Shared Decision Making
Using the DrugAbacus Value Calculator
The NCCN Evidence Blocks
Can Oncologists Perceive the Value of a Treatment?
Filling the Data Gaps, Improving Patient Understanding
Data Fragmentation: A Barrier to Value Constructs
Evaluating the Quality of Evidence Used for Developing Value Frameworks
Rightsizing Drug Distribution to Improve Value
How Do Payers Balance Personalized Care With Population Health?
Cost Implications of Oncology Care for the Patient
Value Equation: Do Patients and Oncologists Agree?
Eliminating Data Silos to Benefit the Patient
Understanding the Drug Developer's Perception of Value
Arguing for the Patient as the Consumer of Healthcare
Can Patients Distinguish Volume From Value in Healthcare?
Stakeholders Define Value in Healthcare
What We're Reading: Consumer Organization Files Lawsuit Against the FDA
What We’re Reading, April 29, 2016: While sales of Gilead's Harvoni drop, NY state attorney's decision could be good news for the company; and the FDA faces a lawsuit from a consumer advocacy group.
Will CMS Accept Offer of a 95% Cheaper Enzalutamide?
A company in Canada, Biolyse Pharma, has offered to manufacture a generic version of enzalutamide at a significantly lower price than what CMS paid in 2014.
Segment 14: The Future of Clinical Pathways
Panel participants provide their perspectives on how they would like to see the field of oncology clinical pathways develop.
Segment 13: Place for Palliative Care in Clinical Pathways
Panelists explain the need and the challenges with including principles of palliative care in oncology clinical pathways.